RecruitingNCT06017518
An Observational Study of Local Relapse After High Grade Osteosarcoma
Sponsor
Istituto Ortopedico Rizzoli
Enrollment
150 participants
Start Date
Jun 13, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
multicenter retrospective and prospective study in patients with high-grade osteosarcoma
Eligibility
Inclusion Criteria4
- Patients who experienced LR as first event of recurrence after treatment for localized high-grade osteosarcoma of bone, including cases with synchronous lung metastases
- Adequate patient compliance to follow-up visits
- Written informed consent prior to any study-specific analysis and/or data collection
- No age limits
Exclusion Criteria2
- Cases of LR demonstrated after \> 3 months after metastatic disease
- Impossibility to ensure adequate compliance
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06017518
Related Trials
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
NCT074797321 location
Upfront Surgical Resection for Osteosarcoma
NCT063844041 location
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
NCT074774577 locations
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT066251901 location
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
NCT034424653 locations